Fig. 4: Efficacy of lorlatinib in patients with MIBG avid relapsed or refractory ALK-driven neuroblastoma. | Nature Medicine

Fig. 4: Efficacy of lorlatinib in patients with MIBG avid relapsed or refractory ALK-driven neuroblastoma.

From: Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Fig. 4: Efficacy of lorlatinib in patients with MIBG avid relapsed or refractory ALK-driven neuroblastoma.

Shown are waterfall plots summarizing the best percentage change from baseline in MIBG avidity (change in overall MIBG Curie score47 (soft tissue and bone avid lesions) from baseline MIBG Curie score). Bar color represents BOR according to NANT response criteria 2.0 (ref. 26). Cohort A1: patients ≥12 months to <18 years of age treated at all DLs with single-agent lorlatinib; cohort A2: patients ≥18 years of age treated with single-agent lorlatinib; cohort B2: patients <18 years of age treated with combination lorlatinib and topotecan/cyclophosphamide.

Source data

Back to article page